Investment
Features
FeesSafety
Academy
More
Pluang+

Beam Therapeutics faces investigation over possible securities fraud after clinical trial data causes stock drop

Market News
15 Oct 2026
PRNewsWire
View Source
Bearish
Beam Therapeutics faces investigation over possible securities fraud after clinical trial data causes stock drop

Pomerantz LLP is investigating Beam Therapeutics and some of its executives for possible securities fraud related to the company's recent clinical trial update. On September 8, 2026, Beam reported Phase 1/2 trial results for BEAM-302, noting safety concerns with transient liver enzyme elevations. Following this announcement, Beam's stock price dropped nearly 10%. The investigation aims to determine if Beam misled investors about the drug's safety profile, which could impact shareholder value and lead to legal action.

Beam Therapeutics is under investigation for possible securities fraud following its clinical trial update. For readers following the health sector, here is Pluang's market snapshot as of Oct 15, 2026 20:51 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 117 rose and 29 fell today. Notable movers include ABEO at USD 4.52 with a 1-day change of +3.67%, GILD at USD 158.51 with +3.24%, and IONS at USD 44.07 with +3.21%.

More News

Stifel reaffirms Buy on Accenture with $242 target amid strong AI-driven growth and 13.4% stock rise.

Stifel reaffirms Buy on Accenture with $242 target amid strong AI-driven growth and 13.4% stock rise.

Stifel Nicolaus has reiterated a Buy rating for Accenture with a price target of $242, reflecting confidence in the company's strong recent stock performance and growth prospects. Accenture's shares rose 13.4% in the month leading up to October 15, 2...

Analyst Insights
Bullish
29 minutes ago
CCC Intelligent Solutions downgraded as $6.1B acquisition offer at $7.75/share announced

CCC Intelligent Solutions downgraded as $6.1B acquisition offer at $7.75/share announced

Investment firm William Blair downgraded CCC Intelligent Solutions to Market Perform amid news of a $6.1 billion acquisition by a consortium led by GTCR and Elliott Investment Management. Shareholders will receive $7.75 per share, a premium over rece...

Market News
Neutral
36 minutes ago
U.S. Bancorp beats Q3 2026 EPS estimates despite slight revenue miss

U.S. Bancorp beats Q3 2026 EPS estimates despite slight revenue miss

U.S. Bancorp reported third-quarter 2026 earnings per share of $1.34, exceeding analyst estimates of $1.32 and marking its fourth consecutive earnings beat. Revenue grew 8.8% year-over-year to $7.97 billion but fell just short of the $8.00 billion ex...

Company Fundamentals
Bullish
41 minutes ago
Vallourec unveils VAM® and expanded CLEANWELL® range at ADIPEC 2026 to boost energy sector efficiency.

Vallourec unveils VAM® and expanded CLEANWELL® range at ADIPEC 2026 to boost energy sector efficiency.

Vallourec, a global leader in premium tubular solutions, will showcase its VAM® product line and the expanded CLEANWELL® grease-free range at ADIPEC 2026 in Abu Dhabi. These offerings aim to enhance operational efficiency and support energy transitio...

Others
Bullish
41 minutes ago
Vallourec unveils VAM® and expanded CLEANWELL® solutions at ADIPEC 2026 to boost energy sector efficiency and sustainability

Vallourec unveils VAM® and expanded CLEANWELL® solutions at ADIPEC 2026 to boost energy sector efficiency and sustainability

At ADIPEC 2026 in Abu Dhabi, Vallourec showcased its VAM® portfolio and the expanded CLEANWELL® range, highlighting innovations that improve operational efficiency and reduce environmental impact in the energy sector. The VAM® connections cater to oi...

Market News
Bullish
41 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App